Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo

J. A. Clowes, G. Z. Eghbali-Fatourechi, L. McCready, Merry Jo Oursler, Sundeep Khosla, B. L. Riggs

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

In bone marrow aspirates from postmenopausal women, systemic estrogen treatment decreased differentiation of mononuclear progenitor cells toward a more mature osteoclast phenotype. This was not associated with changes in surface receptor for proresorptive cytokines. Introduction: Although mechanisms by which estrogen (E) decreases bone resorption have been extensively studied in rodents, little information is available in humans. Methods: In bone marrow aspirates from 34 early postmenopausal women randomly assigned to receive 4 weeks of treatment (100 μg/day of transdermal 17β-estradiol) or no treatment, we assessed osteoclast differentiation and surface receptors using flow cytometry with fluorescent-labeled specific antibodies. Results: E treatment decreased (P∈<∈0.05) the proportion of bone marrow mononuclear cells (BMMNCs) expressing the calcitonin receptor (CTR), a late osteoclast phenotype marker. There was an increase in c-Fms concentration in osteoclast lineage cells (P∈<∈0.05) and in the proportion of BMMNCs expressing TNFR2 (P∈<∈0.05), but there were no significant effects on other surface receptors for proresorptive factors (RANK, TNFR1, TREM2, or OSCAR). Changes in serum CTx and TRAP 5b, markers for bone resorption, correlated directly (P∈<∈0.05) with the proportion of BMMNCs expressing CTR and, for TRAP 5b only, TNFR2 and inversely with c-Fms concentration (all P∈<∈0.05). Conclusion: E reduces bone resorption, in part, by decreasing differentiation of BMMNCs into mature osteoclasts. This action cannot be explained by decreased concentrations of surface receptors for proresorptive factors. The roles of increases in c-Fms concentration and the proportion of TNFR2 (+) cells are unclear.

Original languageEnglish (US)
Pages (from-to)761-769
Number of pages9
JournalOsteoporosis International
Volume20
Issue number5
DOIs
StatePublished - May 2009

Fingerprint

Osteoclasts
Receptors, Tumor Necrosis Factor, Type II
Estrogens
Bone Marrow Cells
Bone Marrow
Bone Resorption
Calcitonin Receptors
Receptors, Tumor Necrosis Factor, Type I
Phenotype
Cytokine Receptors
Therapeutics
Estradiol
Rodentia
Flow Cytometry
Stem Cells
Antibodies
Serum

Keywords

  • Bone resorption
  • Bone resorption markers
  • Cytokines
  • Estrogen
  • Osteoclast differentiation
  • Osteoclast precursors
  • Osteoclasts
  • Postmenopausal women

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. / Clowes, J. A.; Eghbali-Fatourechi, G. Z.; McCready, L.; Oursler, Merry Jo; Khosla, Sundeep; Riggs, B. L.

In: Osteoporosis International, Vol. 20, No. 5, 05.2009, p. 761-769.

Research output: Contribution to journalArticle

Clowes, J. A. ; Eghbali-Fatourechi, G. Z. ; McCready, L. ; Oursler, Merry Jo ; Khosla, Sundeep ; Riggs, B. L. / Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo. In: Osteoporosis International. 2009 ; Vol. 20, No. 5. pp. 761-769.
@article{30583beafdaa430fad35b5202b139879,
title = "Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo",
abstract = "In bone marrow aspirates from postmenopausal women, systemic estrogen treatment decreased differentiation of mononuclear progenitor cells toward a more mature osteoclast phenotype. This was not associated with changes in surface receptor for proresorptive cytokines. Introduction: Although mechanisms by which estrogen (E) decreases bone resorption have been extensively studied in rodents, little information is available in humans. Methods: In bone marrow aspirates from 34 early postmenopausal women randomly assigned to receive 4 weeks of treatment (100 μg/day of transdermal 17β-estradiol) or no treatment, we assessed osteoclast differentiation and surface receptors using flow cytometry with fluorescent-labeled specific antibodies. Results: E treatment decreased (P∈<∈0.05) the proportion of bone marrow mononuclear cells (BMMNCs) expressing the calcitonin receptor (CTR), a late osteoclast phenotype marker. There was an increase in c-Fms concentration in osteoclast lineage cells (P∈<∈0.05) and in the proportion of BMMNCs expressing TNFR2 (P∈<∈0.05), but there were no significant effects on other surface receptors for proresorptive factors (RANK, TNFR1, TREM2, or OSCAR). Changes in serum CTx and TRAP 5b, markers for bone resorption, correlated directly (P∈<∈0.05) with the proportion of BMMNCs expressing CTR and, for TRAP 5b only, TNFR2 and inversely with c-Fms concentration (all P∈<∈0.05). Conclusion: E reduces bone resorption, in part, by decreasing differentiation of BMMNCs into mature osteoclasts. This action cannot be explained by decreased concentrations of surface receptors for proresorptive factors. The roles of increases in c-Fms concentration and the proportion of TNFR2 (+) cells are unclear.",
keywords = "Bone resorption, Bone resorption markers, Cytokines, Estrogen, Osteoclast differentiation, Osteoclast precursors, Osteoclasts, Postmenopausal women",
author = "Clowes, {J. A.} and Eghbali-Fatourechi, {G. Z.} and L. McCready and Oursler, {Merry Jo} and Sundeep Khosla and Riggs, {B. L.}",
year = "2009",
month = "5",
doi = "10.1007/s00198-008-0731-y",
language = "English (US)",
volume = "20",
pages = "761--769",
journal = "Osteoporosis International",
issn = "0937-941X",
publisher = "Springer London",
number = "5",

}

TY - JOUR

T1 - Estrogen action on bone marrow osteoclast lineage cells of postmenopausal women in vivo

AU - Clowes, J. A.

AU - Eghbali-Fatourechi, G. Z.

AU - McCready, L.

AU - Oursler, Merry Jo

AU - Khosla, Sundeep

AU - Riggs, B. L.

PY - 2009/5

Y1 - 2009/5

N2 - In bone marrow aspirates from postmenopausal women, systemic estrogen treatment decreased differentiation of mononuclear progenitor cells toward a more mature osteoclast phenotype. This was not associated with changes in surface receptor for proresorptive cytokines. Introduction: Although mechanisms by which estrogen (E) decreases bone resorption have been extensively studied in rodents, little information is available in humans. Methods: In bone marrow aspirates from 34 early postmenopausal women randomly assigned to receive 4 weeks of treatment (100 μg/day of transdermal 17β-estradiol) or no treatment, we assessed osteoclast differentiation and surface receptors using flow cytometry with fluorescent-labeled specific antibodies. Results: E treatment decreased (P∈<∈0.05) the proportion of bone marrow mononuclear cells (BMMNCs) expressing the calcitonin receptor (CTR), a late osteoclast phenotype marker. There was an increase in c-Fms concentration in osteoclast lineage cells (P∈<∈0.05) and in the proportion of BMMNCs expressing TNFR2 (P∈<∈0.05), but there were no significant effects on other surface receptors for proresorptive factors (RANK, TNFR1, TREM2, or OSCAR). Changes in serum CTx and TRAP 5b, markers for bone resorption, correlated directly (P∈<∈0.05) with the proportion of BMMNCs expressing CTR and, for TRAP 5b only, TNFR2 and inversely with c-Fms concentration (all P∈<∈0.05). Conclusion: E reduces bone resorption, in part, by decreasing differentiation of BMMNCs into mature osteoclasts. This action cannot be explained by decreased concentrations of surface receptors for proresorptive factors. The roles of increases in c-Fms concentration and the proportion of TNFR2 (+) cells are unclear.

AB - In bone marrow aspirates from postmenopausal women, systemic estrogen treatment decreased differentiation of mononuclear progenitor cells toward a more mature osteoclast phenotype. This was not associated with changes in surface receptor for proresorptive cytokines. Introduction: Although mechanisms by which estrogen (E) decreases bone resorption have been extensively studied in rodents, little information is available in humans. Methods: In bone marrow aspirates from 34 early postmenopausal women randomly assigned to receive 4 weeks of treatment (100 μg/day of transdermal 17β-estradiol) or no treatment, we assessed osteoclast differentiation and surface receptors using flow cytometry with fluorescent-labeled specific antibodies. Results: E treatment decreased (P∈<∈0.05) the proportion of bone marrow mononuclear cells (BMMNCs) expressing the calcitonin receptor (CTR), a late osteoclast phenotype marker. There was an increase in c-Fms concentration in osteoclast lineage cells (P∈<∈0.05) and in the proportion of BMMNCs expressing TNFR2 (P∈<∈0.05), but there were no significant effects on other surface receptors for proresorptive factors (RANK, TNFR1, TREM2, or OSCAR). Changes in serum CTx and TRAP 5b, markers for bone resorption, correlated directly (P∈<∈0.05) with the proportion of BMMNCs expressing CTR and, for TRAP 5b only, TNFR2 and inversely with c-Fms concentration (all P∈<∈0.05). Conclusion: E reduces bone resorption, in part, by decreasing differentiation of BMMNCs into mature osteoclasts. This action cannot be explained by decreased concentrations of surface receptors for proresorptive factors. The roles of increases in c-Fms concentration and the proportion of TNFR2 (+) cells are unclear.

KW - Bone resorption

KW - Bone resorption markers

KW - Cytokines

KW - Estrogen

KW - Osteoclast differentiation

KW - Osteoclast precursors

KW - Osteoclasts

KW - Postmenopausal women

UR - http://www.scopus.com/inward/record.url?scp=63949087888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63949087888&partnerID=8YFLogxK

U2 - 10.1007/s00198-008-0731-y

DO - 10.1007/s00198-008-0731-y

M3 - Article

C2 - 18769961

AN - SCOPUS:63949087888

VL - 20

SP - 761

EP - 769

JO - Osteoporosis International

JF - Osteoporosis International

SN - 0937-941X

IS - 5

ER -